Top Management Presentation Financial Results of FY2018 Q2
(April 1 - September 30, 2018)

from the beginning

Top Management Presentation Financial Results of FY2018 Q2 (April 1 - September 30, 2018)

Forward-Looking Statements

Agenda

FY2018 Q2 Financial Results

Overview of FY2018 Q2 Results

Revenue

Operating Profit

Special Items

Profit Attributable to Owners of the Company

Revenue: Major Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

@

@

FY2018 Consolidated Forecast

FY2018 Consolidated Forecast

Business Update

Lixiana: Growth in Japan

Edoxaban: Growth in Each Country

LPI: Growth of Injectafer

Revised Target for 5-Year Business Plan

Current Progress of 5-Year Business Plan

Current Progress of 5-Year Business Plan: Oncology Business

Current Progress of 5-Year Business Plan: ADC Franchise

Policy to Revise the 5-Year Business Plan

5-Year Business Plan (Original)

Revised Target for 5-Year Business Plan

Toward 2025 Vision

Mid-term Measures

Cash Allocation Image

Shareholder Returns

Oncology Business: Increase Investments

Oncology Business: Revenue Target

Toward 2025 Vision

R&D Update

Agenda

List of ADC Franchise

Summary of ADC Franchise

DS-8201: Clinical Program

DS-8201: Update

DS-8201: Study Design of Phase 1 Study

DS-8201: Demographics and Baseline Characteristics of NSCLC and CRC Patients (P1 Part 2d)

DS-8201: Phase 1 Part 2d NSCLC Efficacy

DS-8201: Phase 1 NSCLC Example CT Image from Responder

DS-8201: Phase 1 Part 2d CRC Efficacy

DS-8201: Frequent TEAEs (≧20%) (all tumor types from part 1 and part 2)

DS-8201: Adverse Events of Special Interest (all tumor types from part 1 and part 2)

DS-8201：HER2 Low BC Phase 3 Target Population

DS-8201: Hypothesis of IO Combo Effect

DS-8201: Strategy of IO Combo

DS-8201: Pembrolizumab combo P1b Study

DS-8201: Avelumab Combo P1b Study

Other Update

Next Data Points until R&D Day

R&D Day 2018

Appendix

FY2018 R&D Milestone Events

Major R&D Pipeline (Oncology)

Major R&D Pipeline (SM/Vaccine)

Out-licensing Projects

DS-8201: P1b Nivolumab Combination Study (US/EU)

DS-8201 BC Pivotal P2 Study

DS-8201 BC P3 Study vs Physician’s Choice

DS-8201 BC P3 Study vs T-DM1

Abbreviations

Contact address regarding this material

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10

• Q&A 11